SCHEMBL4183301

SCHEMBL4183301

CCCCc1ccc(-n2cccn2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
KMT2A Q03164 2/20 0.47
GRN P28799 1/20 0.46
SORT1 Q99523 1/20 0.46
KDM4E B2RXH2 4/20 0.43
NFKB1 P19838 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
ALDH1A1 P00352 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
THPO P40225 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13514043 0.91 LMNA (0.50) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL13699068 0.85 LMNA (0.45) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL4178530 0.84 LMNA (0.53) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL13625691 0.81 LMNA (0.47) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL13699177 0.80 ADORA2A (0.37) LMNAKMT2AKDM4ENFKB1L3MBTL1
SCHEMBL25428781 0.79 KDM5A (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL18338880 0.78 LMNA (0.53) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL1599534 0.78 LMNA (0.56) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL17159482 0.78 LMNA (0.53) LMNAKMT2AGRNSORT1KDM4E
SCHEMBL14638384 0.78 LMNA (0.56) LMNAKMT2AGRNSORT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589067-B2 6, 11-bridged tricyclic macrolides ENANTA PHARMACEUTICALS, INC. (US) 2009-09-15 US disclosed
US-20090143440-A1 Pyrazoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-06-04 US disclosed
WO-2008019240-A2 3, 6-BRIDGED TYLOSIN DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2008-02-14 WO disclosed
US-20080039406-A1 3,6-BRIDGED TYLOSIN DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2008-02-14 US disclosed
US-20070082853-A1 6, 11-bridged tricyclic macrolides ENANTA PHARMACEUTICAL, INC. 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143440-A1 Pyrazoles Useful in the Treatment of Inflammation ALOX15, ALOX12, ALOX15B LMNA 1666/4885KMT2A 4450/4885GRN 2104/4885
US-20070082853-A1 6, 11-bridged tricyclic macrolides CYP2B6, CYP2D6, ABCB11 LMNA 3616/4885KMT2A 3679/4885GRN 2969/4885
US-20080039406-A1 3,6-BRIDGED TYLOSIN DERIVATIVES ABCB11, ABCB1, CYP2B6 LMNA 3009/4885KMT2A 3455/4885GRN 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.